FRA:MRK

MERCK Kommanditgesellschaft auf Aktien News Headlines

€196.50
+0.15 (+0.08 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
€195.20
€199.25
50-Day Range
€167.65
€206.10
52-Week Range
€76.60
€115.00
Volume910,646 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Media Mentions By Week

MERCK Kommanditgesellschaft auf Aktien Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MRK
News Sentiment

-0.17

0.31

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MRK Articles
This Week

2

0

MRK Articles
Average Week

Get MERCK Kommanditgesellschaft auf Aktien News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

MERCK Kommanditgesellschaft auf Aktien (FRA MRK) News Headlines Today

SourceHeadline
Supply fears lead EU vaccine industry to seek home comfortsSupply fears lead EU vaccine industry to seek home comforts
finance.yahoo.com - September 17 at 3:28 AM
MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Stock Passes Above 50 Day Moving Average of $185.65MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) Stock Passes Above 50 Day Moving Average of $185.65
americanbankingnews.com - September 15 at 2:00 AM
MORNING BID-A tense finishMORNING BID-A tense finish
finance.yahoo.com - June 29 at 4:28 AM
Signature Resources Announces $3.5 Million Non-Brokered Private Placement LED by Commodity Discovery Fund, Funds Managed by Sprott Asset Management LP & Crescat CapitalSignature Resources Announces $3.5 Million Non-Brokered Private Placement LED by Commodity Discovery Fund, Funds Managed by Sprott Asset Management LP & Crescat Capital
finance.yahoo.com - June 21 at 9:29 AM
This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?This New Product Is Central to mRNA Vaccines -- But Should You Buy the Stock?
finance.yahoo.com - June 9 at 12:27 PM
UPDATE 1-Lab supplier Merck KGaA says U.S. Defense Production Act poses challengeUPDATE 1-Lab supplier Merck KGaA says U.S. Defense Production Act poses challenge
finance.yahoo.com - May 12 at 7:00 AM
MORNING BID-Covid, missiles and tanker tailbacksMORNING BID-Covid, missiles and tanker tailbacks
finance.yahoo.com - March 25 at 4:39 AM
MERCK Kommanditgesellschaft auf Aktien (MRK1N.MX)MERCK Kommanditgesellschaft auf Aktien (MRK1N.MX)
ca.finance.yahoo.com - March 11 at 8:40 AM
Germanys Merck KGaA predicts earnings gain in 2021 on lab gearGermany's Merck KGaA predicts earnings gain in 2021 on lab gear
finance.yahoo.com - March 4 at 4:25 AM
Hydrophobic Interaction Chromatography Resins Market (2020-29): Demand and Scope, Industry Trends and Threats | Tosoh Corporation, Pall CorporationHydrophobic Interaction Chromatography Resins Market (2020-29): Demand and Scope, Industry Trends and Threats | Tosoh Corporation, Pall Corporation
marketwatch.com - December 27 at 1:06 AM
Superdisintegrants Market (2020-29): Extensive Growth, Rising Demand and Strategies | BASF SE, DFE PharmaSuperdisintegrants Market (2020-29): Extensive Growth, Rising Demand and Strategies | BASF SE, DFE Pharma
marketwatch.com - December 25 at 7:16 AM
MERCK Kommanditgesellschaft auf Aktien: Merck KGaA Benefiting From COVID-Related Development Projects; Maintaining Fair Value EstimateMERCK Kommanditgesellschaft auf Aktien: Merck KGaA Benefiting From COVID-Related Development Projects; Maintaining Fair Value Estimate
finance.yahoo.com - November 14 at 10:38 PM
Digital Leaders from Almirall and Merck KGaA, Darmstadt, Germany to Keynote Veeva Summit Online, EuropeDigital Leaders from Almirall and Merck KGaA, Darmstadt, Germany to Keynote Veeva Summit Online, Europe
markets.businessinsider.com - November 3 at 4:14 AM
Merck sets ultra-high bar with impressive development of KeytrudaMerck sets ultra-high bar with impressive development of Keytruda
seekingalpha.com - October 31 at 7:26 PM
Merck sets ulta-high bar with impressive development of KeytrudaMerck sets ulta-high bar with impressive development of Keytruda
seekingalpha.com - October 30 at 12:22 PM
Merck EPS beats by $0.31, beats on revenueMerck EPS beats by $0.31, beats on revenue
seekingalpha.com - October 28 at 12:29 PM
Merck says early data from COVID-19 vaccines expected this yearMerck says early data from COVID-19 vaccines expected this year
reuters.com - October 28 at 7:24 AM
Merck up 2% premarket on Q3 beat; FY20 non-GAAP EPS guidance raisedMerck up 2% premarket on Q3 beat; FY20 non-GAAP EPS guidance raised
seekingalpha.com - October 27 at 10:01 AM
Merck quarterly profit rises nearly 55% as key drug sales reboundMerck quarterly profit rises nearly 55% as key drug sales rebound
reuters.com - October 27 at 10:01 AM
Merck raises annual profit outlook as Keytruda drives profit beatMerck raises annual profit outlook as Keytruda drives profit beat
reuters.com - October 27 at 10:01 AM
Merck Q3 2020 Earnings PreviewMerck Q3 2020 Earnings Preview
seekingalpha.com - October 26 at 5:23 PM
Merck Reports Positive Data From 2 Trials Of V114 Pneumococcal Conjugate VaccineMerck Reports Positive Data From 2 Trials Of V114 Pneumococcal Conjugate Vaccine
markets.businessinsider.com - October 20 at 7:36 AM
Mercks 15-valent pneumonia vaccine successful in two more late-stage studiesMerck's 15-valent pneumonia vaccine successful in two more late-stage studies
seekingalpha.com - October 20 at 7:36 AM
Mercks Keytruda/chemo combo shows durable, sustained benefit in long term lung cancer studyMerck's Keytruda/chemo combo shows durable, sustained benefit in long term lung cancer study
seekingalpha.com - October 16 at 6:55 PM
MERCK KGAA Inhaber-Aktien o.N. (MRK.SG)MERCK KGAA Inhaber-Aktien o.N. (MRK.SG)
ca.finance.yahoo.com - October 16 at 1:55 PM
A German drugmaker just increased its stake in this Md. biopharma — and it showed in the stock priceA German drugmaker just increased its stake in this Md. biopharma — and it showed in the stock price
bizjournals.com - October 12 at 4:56 PM
Merck HIV combo regimen shows sustained benefit in mid-stage HIV studyMerck HIV combo regimen shows sustained benefit in mid-stage HIV study
seekingalpha.com - October 8 at 12:47 PM
Merck Mid-stage HIV Study On Islatravir- Doravirine Shows Viral Suppression MaintainedMerck Mid-stage HIV Study On Islatravir- Doravirine Shows Viral Suppression Maintained
nasdaq.com - October 8 at 12:47 PM
New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%
baystreet.ca - October 7 at 11:43 AM
Merck Inc (MRK) EVP, Global Svcs & CFO Robert M Davis Sold $20.4 million of SharesMerck Inc (MRK) EVP, Global Svcs & CFO Robert M Davis Sold $20.4 million of Shares
uk.finance.yahoo.com - October 6 at 10:49 PM
Merck Banks on Keytruda, Pipeline & Deals Amid Generic WoesMerck Banks on Keytruda, Pipeline & Deals Amid Generic Woes
nasdaq.com - October 2 at 12:44 PM
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal CancerCelyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
nasdaq.com - September 29 at 7:30 PM
Merck Enbrel biosimilar OKd in Canada for four new usesMerck Enbrel biosimilar OK'd in Canada for four new uses
seekingalpha.com - September 15 at 8:56 AM
Merck: Health Canada Approves BRENZYS For Four New IndicationsMerck: Health Canada Approves BRENZYS For Four New Indications
nasdaq.com - September 15 at 8:56 AM
Merck (Finally) Starts a Clinical Trial of its Coronavirus VaccineMerck (Finally) Starts a Clinical Trial of its Coronavirus Vaccine
fool.com - September 14 at 12:16 AM
Merck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 TrialsMerck: Gefapixant Significantly Reduced Cough Frequency Compared To Placebo In Two Phase 3 Trials
nasdaq.com - September 8 at 9:19 AM
Merck To Present New Data From Oncology Development Program At ESMO Virtual CongressMerck To Present New Data From Oncology Development Program At ESMO Virtual Congress
nasdaq.com - September 2 at 10:11 AM
Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?
nasdaq.com - August 30 at 2:53 PM
Merck : Phase 3 Study Of KEYTRUDA - Chemotherapy On Metastatic Esophageal Cancer Meets Main GoalMerck : Phase 3 Study Of KEYTRUDA - Chemotherapy On Metastatic Esophageal Cancer Meets Main Goal
nasdaq.com - August 19 at 8:20 AM
Merck in-licenses NASH candidate from Hanmi PharmaceuticalMerck in-licenses NASH candidate from Hanmi Pharmaceutical
seekingalpha.com - August 4 at 7:29 AM
Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 PipelineGoldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
www.msn.com - August 3 at 1:09 PM
Merck Posts Second-Quarter Earnings Beat and Lifts GuidanceMerck Posts Second-Quarter Earnings Beat and Lifts Guidance
www.thestreet.com - July 31 at 8:04 AM
Pharma giant Merck raises 2020 outlook, saying the worst of the coronavirus impact is behind itPharma giant Merck raises 2020 outlook, saying the worst of the coronavirus impact is behind it
www.cnbc.com - July 31 at 8:04 AM
Earnings Preview: Merck (MRK) Q2 Earnings Expected to DeclineEarnings Preview: Merck (MRK) Q2 Earnings Expected to Decline
www.nasdaq.com - July 24 at 2:53 PM
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer FightNew Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
www.marketwatch.com - July 21 at 8:41 AM
Novocure teams up with Merck in lung cancer studyNovocure teams up with Merck in lung cancer study
seekingalpha.com - July 15 at 9:08 AM
Merck: Amazing Oncology Division, Underwhelming Dividend OpportunityMerck: Amazing Oncology Division, Underwhelming Dividend Opportunity
seekingalpha.com - July 9 at 1:04 PM
Pfizers sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU NodPfizer's sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU Nod
finance.yahoo.com - July 3 at 5:51 PM
Mercks Keytruda Wins FDA Nod for Squamous Cell Skin CancerMerck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
www.nasdaq.com - June 25 at 1:18 PM
Merck teams up with Yumanity in neurodegenerative diseasesMerck teams up with Yumanity in neurodegenerative diseases
seekingalpha.com - June 24 at 12:14 PM
Get MERCK Kommanditgesellschaft auf Aktien News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.